Clinical and Translational Evaluation of a Lactobacillus Acidophilus Respiratory Mucosal Barrier Platform

Abstract

Background: Respiratory mucosal resilience depends on epithelial integrity, mucosal hydration, microbiome–host communication, and local secretory IgA activity. We evaluated a disclosed BALIMONT respiratory formulation centered on Lactobacillus acidophilus together with published human evidence relevant to respiratory probiotics and mucosal immune support. Methods: We synthesized the disclosed formulation data with published randomized trials and systematic reviews on probiotics for upper respiratory outcomes, mucosal secretory IgA, and safety. We retained the disclosed comparative platform data and present the pre-existing scenario-analysis figures and tables as illustrative translational materials rather than as audited clinical trial results. Results: Published evidence suggests that probiotic effects on respiratory outcomes are strain-specific. In healthy physically active adults, Bifidobacterium animalis subsp. lactis Bl-04 reduced the risk of upper respiratory illness versus placebo (hazard ratio 0.73). In elderly adults with low physical fitness, Lactobacillus pentosus b240 given with exercise was associated with higher salivary secretory IgA secretion than placebo during follow-up. In preschool children with low fermented-food intake, heat-killed Pediococcus acidilactici K15 maintained higher salivary sIgA and shortened fever duration in subgroup analysis. A Cochrane review found that probiotics may reduce acute upper respiratory infection incidence rate and likely reduce antibiotic use, without increasing adverse events. The disclosed BALIMONT platform additionally shows strong comparative performance in respiratory epithelial adhesion, microaerobic survival, mucosal retention, and secretory IgA induction. Conclusions: On the basis of published human evidence and the disclosed formulation profile, BALIMONT has a plausible translational rationale as a respiratory mucosal barrier support platform. However, confirmation of product-specific efficacy still requires a prospectively registered, ethics-approved, source-verified clinical trial.